Literature DB >> 12823692

Pathological effects of neoadjuvant hormonal therapy help predict progression of prostate cancer after radical prostatectomy.

Yasuhide Kitagawa1, Kiyoshi Koshida, Atsushi Mizokami, Kazuto Komatsu, Shinichi Nakashima, Toshimitsu Misaki, Tetsuo Katsumi, Mikio Namiki.   

Abstract

BACKGROUND: It is not clear whether pathological changes following neoadjuvant hormonal therapy (NHT) prior to radical prostatectomy have any value as predictors of progression in prostate cancer.
METHODS: We conducted a study of 100 patients with prostate cancer who underwent radical prostatectomy following NHT. We used the Japanese general rule as the criterion to assess the biochemical recurrence rate and pathological changes after NHT.
RESULTS: In terms of preoperative risk factors, the probability of recurrence was significantly higher for patients with more than 20 ng/mL of pretreatment serum prostate-specific antigen (PSA) and/or a Gleason score of 7 or higher for biopsy specimens. We defined these pretreatment findings as high-risk factors. Among 65 patients with high-risk factors, patients with a post-NHT pathological effect of grade 3 according to the Japanese general rule showed no recurrence, whereas patients with a grade 0 had a poor prognosis. Patients with a PSA nadir 0.5 ng/mL or less tended to have a better prognosis.
CONCLUSION: Despite preoperative high-risk factors, patients showing good pathological effects after NHT tend to have a favorable prognosis after radical prostatectomy. Therefore; assessment of the pathological effects of NHT using the Japanese general rule as the criterion proved to be useful for the prediction of biochemical recurrence.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12823692     DOI: 10.1046/j.1442-2042.2003.00640.x

Source DB:  PubMed          Journal:  Int J Urol        ISSN: 0919-8172            Impact factor:   3.369


  8 in total

1.  Clinical efficacy of primary combined androgen blockade for Japanese men with clinically localized prostate cancer unsuitable for local definitive treatment: a single institution experience.

Authors:  Minoru Kobayashi; Akinori Nukui; Kazumi Suzuki; Shinsuke Kurokawa; Tatsuo Morita
Journal:  Int J Clin Oncol       Date:  2011-04-23       Impact factor: 3.402

Review 2.  Effectiveness and adverse effects of hormonal therapy for prostate cancer: Japanese experience and perspective.

Authors:  Mikio Namiki; Satoru Ueno; Yasuhide Kitagawa; Takashi Fukagai; Hideyuki Akaza
Journal:  Asian J Androl       Date:  2012-03-26       Impact factor: 3.285

3.  Bone marrow metastasis of prostatic adenocarcinoma with post-treatment foamy-like changes: A diagnostic pitfall.

Authors:  Nuri Yigit; Julia Turbiner Geyer
Journal:  Can Urol Assoc J       Date:  2014-11       Impact factor: 1.862

Review 4.  Hormonal therapy.

Authors:  Mikio Namiki; Satoru Ueno; Yasuhide Kitagawa; Hiroyuki Konaka; Atsushi Mizokami; Eitetsu Koh; Takashi Fukagai
Journal:  Int J Clin Oncol       Date:  2007-12-21       Impact factor: 3.402

5.  Duration of androgen deprivation therapy with maximum androgen blockade for localized prostate cancer.

Authors:  Naohiro Fujimoto; Tatsuhiko Kubo; Hideo Shinsaka; Masahiro Matsumoto; Shohei Shimajiri; Tetsuro Matsumoto
Journal:  BMC Urol       Date:  2011-05-14       Impact factor: 2.264

6.  Risk factors of PSA progression and overall survival in patients with localized and locally advanced prostate cancer treated with primary androgen deprivation therapy.

Authors:  Atsushi Tomioka; Nobumichi Tanaka; Motokiyo Yoshikawa; Makito Miyake; Satoshi Anai; Yoshitomo Chihara; Eijiro Okajima; Akihide Hirayama; Yoshihiko Hirao; Kiyohide Fujimoto
Journal:  BMC Cancer       Date:  2015-05-20       Impact factor: 4.430

7.  Patient-derived tissue slice grafts accurately depict response of high-risk primary prostate cancer to androgen deprivation therapy.

Authors:  Hongjuan Zhao; Alan Thong; Rosalie Nolley; Stephen W Reese; Jennifer Santos; Alexandre Ingels; Donna M Peehl
Journal:  J Transl Med       Date:  2013-08-28       Impact factor: 5.531

Review 8.  Role of hormonal therapy for prostate cancer: perspective from Japanese experiences.

Authors:  Mikio Namiki; Satoru Ueno; Yasuhide Kitagawa
Journal:  Transl Androl Urol       Date:  2012-09
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.